REFERENCES
1. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr., Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019; 380 (1): 11–22. https://doi.org/10.1056/NEJMoa1812792.
2. Arai H, Ishibashi S, Bujo H, Hayashi T, Yokoyama S, Oikawa S, Kobayashi J, Shirai K, Ota T, Yamashita S, Gotoda T, Harada-Shiba M, Sone H, Eto M, Suzuki H, Yamada N. Management of type IIb dyslipidemia.J Atheroscler Thromb. 2012; 19 (2): 105–114. https://doi.org/10.5551/jat.10447.
3. Schaefer JR. Unraveling hyperlipidemia type III (dysbetalipoproteinemia), slowly. Eur J Hum Genet. 2009;17 (5): 541–542. https://doi.org/10.1038/ejhg.2008.222.
4. Maharaj S, Chang S, Nayak SB. Familial hypercholesterolemia presenting with multiple nodules of the hands and elbow. Clin Case Rep. 2015; 3 (6): 411–414. https://doi.org/10.1002/ccr3.249.
5. Harada-Shiba M, Arai H, Ishigaki Y, Ishibashi S, Okamura T, Ogura M, Dobashi K, Nohara A, Bujo H, Miyauchi K, Yamashita S, Yokote K. Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017. J Atheroscler Thromb. 2018; 25 (8): 751–770. https://doi.org/10.5551/jat.CR003.
6. Roga G, Jithendriya M. Eruptive xanthoma: Warning sign of systemic disease. Cleve Clin J Med. 2016; 83 (10): 715–716. https://doi.org/10.3949/ccjm.83a.15126.
7. Solak B, Kara RO, Acikgoz SB, Kosem M. First and only symptom of undiagnosed diabetes mellitus: eruptive xanthoma. BMJ Case Rep.2015; 2015 : bcr2015212160. https://doi.org/10.1136/bcr-2015-212160.
8. Tsuchiya S, Sawada S, Takeda K, Takahashi K, Nakajima T, Kohata M, Kurosawa S, Satake C, Imai J, Kikuchi K, Aiba S, Katagiri H. Eruptive xanthomas in a patient with soft-drink diabetic ketosis and apolipoprotein E4/2. Endocr J. 2019; 66 (1): 107–114. https://doi.org/10.1507/endocrj.EJ18-0356.
9. Kashif M, Kumar H, Khaja M. An unusual presentation of eruptive xanthoma: A case report and literature review. Medicine (Baltimore). 2016; 95 (37): e4866. https://doi.org/10.1097/MD.0000000000004866.
10. Abdelghany M, Massoud S. Eruptive xanthoma. Cleve Clin J Med.2015; 82 (4): 209–210. https://doi.org/10.3949/ccjm.82a.14081.
11. Zaremba J, Zaczkiewicz A, Placek W. Eruptive xanthomas.Postepy Dermatol Alergol. 2013; 30 (6): 399–402. https://doi.org/10.5114/pdia.2013.39439.
12. Zak A, Zeman M, Slaby A, Vecka M. Xanthomas: clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014; 158 (2): 181–188. https://doi.org/10.5507/bp.2014.016.
13. Sandhu S, Al-Sarraf A, Taraboanta C, Frohlich J, Francis GA. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis. 2011; 10 : 157. https://doi.org/10.1186/1476-511X-10-157.
14. Boullart ACI, de Graaf J, Stalenhoef AF. Serum triglycerides and risk of cardiovascular disease. Biochim Biophys Acta. 2012;1821 (5): 867–875. https://doi.org/10.1016/j.bbalip.2011.10.002.
15. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012; 148(5): 852–871. https://doi.org/10.1016/j.cell.2012.02.017.
16. Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab. 2013;17 (2): 185–196. https://doi.org/10.1016/j.cmet.2013.01.001.
17. Zhou Y, Rui L. Leptin signaling and leptin resistance. Front Med. 2013; 7 (2): 207–222. https://doi.org/10.1007/s11684-013-0263-5.
18. Grant RW, Dixit VD. Adipose tissue as an immunological organ.Obesity (Silver Spring). 2015; 23 (3): 512–518. https://doi.org/10.1002/oby.21003.
19. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010; 140 (6): 900–917. https://doi.org/10.1016/j.cell.2010.02.034.
20. Teo CF, Wollaston-Hayden EE, Wells L. Hexosamine flux, the O-GlcNAc modification, and the development of insulin resistance in adipocytes.Mol Cell Endocrinol. 2010; 318 (1-2): 44–53. http://doi.org/10.1016/j.mce.2009.09.022.
21. Romeo S, Yin W, Kozlitina J, Pennacchio LA, Boerwinkle E, Hobbs HH, Cohen JC. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest. 2009; 119 (1): 70–79. https://doi.org/10.1172/JCI37118.
22. Inukai K, Nakashima Y, Watanabe M, Kurihara S, Awata T, Katagiri H, Oka Y, Katayama S. ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states. Biochem Biophys Res Commun. 2004;317 (4): 1075–1079. https://doi.org/10.1016/j.bbrc.2004.03.151.
23. Shimamura M, Matsuda M, Kobayashi S, Ando Y, Ono M, Koishi R, Furukawa H, Makishima M, Shimomura I. Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes.Biochem Biophys Res Commun. 2003; 301 (2): 604–609. https://doi.org/10.1016/s0006-291x(02)03058-9.
24. Chen PY, Gao WY, Liou JW, Lin CY, Wu MJ, Yen JH. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.Int J Mol Sci. 2021; 22 (14): 7310. https://doi.org/10.3390/ijms22147310.
25. Toth PP. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag. 2016;12 : 171–183. https://doi.org/10.2147/VHRM.S104369. 26. Lusis AJ. Atherosclerosis. Nature. 2000. 14; 407(6801): 233–241. https://doi.org/10.1038/35025203.
27. Parhofer KG, Laufs U. The Diagnosis and Treatment of Hypertriglyceridemia. Dtsch Arztebl Int. 2019; 116 (49): 825–832. https://doi.org/10.3238/arztebl.2019.0825.
28. Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T, Shimamoto T, Iida M, Komachi Y. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol. 2001; 153 (5): 490–499. https://doi.org/10.1093/aje/153.5.490.
29. Marston NA, Giugliano RP, Im K, Silverman MG, O’Donoghue ML, Wiviott SD, Ference BA, Sabatine MS. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation. 2019;140 (16): 1308–1317. https://doi.org/10.1161/CIRCULATIONAHA.119.041998.
30. Masuda D, Yamashita S. Postprandial Hyperlipidemia and Remnant Lipoproteins. J Atheroscler Thromb. 2017; 24 (2): 95–109. https://doi.org/10.5551/jat.RV16003.
31. Alipour A, Valdivielso P, Elte JWF, Janssen HW, Rioja J, van der Meulen N, Mechelen R, Njo TL, González-Santos P, Rietveld AP, Cabezas MC. Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice. Eur J Clin Invest. 2012; 42 (7): 702–708. https://doi.org/10.1111/j.1365-2362.2011.02635.x.
32. Masuda D, Sugimoto T, Tsujii K, Inagaki M, Nakatani K, Yuasa-Kawase M, Tsubakio-Yamamoto K, Ohama T, Nishida M, Ishigami M, Kawamoto T, Matsuyama A, Sakai N, Komuro I, Yamashita S. Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence.Eur J Clin Invest. 2012; 42 (9): 992–999. https://doi.org/10.1111/j.1365-2362.2012.02687.x.